The HBV drug entecavir - Effects on HIV-1 replication and resistance

Moira A. McMahon, Benjamin L. Jilek, Timothy P. Brennan, Lin Shen, Yan Zhou, Megan Wind-Rotolo, Sifei Xing, Shridhar Bhat, Braden Hale, Robert Hegarty, Curtis R. Chong, Jun O. Liu, Robert F. Siliciano, Chloe L. Thio

Research output: Contribution to journalArticlepeer-review

223 Scopus citations


Entecavir, a drug approved by the Food and Drug Administration for the treatment of chronic hepatitis B virus (HBV) infection, is not believed to inhibit replication of human immunodeficiency virus type 1 (HIV-1) at clinically relevant doses. We observed that entecavir led to a consistent 1-log 10 decrease in HIV-1 RNA in three persons with HIV-1 and HBV coinfection, and we obtained supportive in vitro evidence that entecavir is a potent partial inhibitor of HIV-1 replication. Detailed analysis showed that in one of these patients, entecavir monotherapy led to an accumulation of HIV-1 variants with the lamivudine-resistant mutation, M184V. In vitro experiments showed that M184V confers resistance to entecavir. Until more is known about HIV-1-resistance patterns and their selection by entecavir, caution is needed with the use of entecavir in persons with HIV-1 and HBV coinfection who are not receiving fully suppressive antiretroviral regimens.

Original languageEnglish (US)
Pages (from-to)2614-2621
Number of pages8
JournalNew England Journal of Medicine
Issue number25
StatePublished - Jun 21 2007

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'The HBV drug entecavir - Effects on HIV-1 replication and resistance'. Together they form a unique fingerprint.

Cite this